Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Effect of GLP-1 (7-36) and GLP-1 (9-36) on Vascular Function
NCT02333591Phase 4Completed
- Start
- Jul 2016
- Primary completion
- Jun 2018
- Modality
- Peptides, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 4, randomised, double-blind trial of Glucagon-like peptide 1 and glp-1-(9,36)amide in Coronary Microvascular Dysfunction (CMD) (3 arms). Primary endpoint: Coronary Flow Reserve at 2 hours. Started Jul 2016; status: completed.
02
Drugs
Glucagon-like peptide 1glp-1-(9,36)amide
03
Conditions
Coronary Microvascular Dysfunction (CMD)
Beyond the preview
Go deeper on NCT02333591.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02333591.